Low-temperature emulsified water-in-oil-in-water adjuvant, and use method and application thereof
By using a combination of vegetable oil and surfactant at low temperatures, the emulsification and stability of water-in-oil adjuvant in water is achieved, and the problem of high-temperature emulsification is solved. The destruction and stability of antigens by high-temperature emulsification is solved, reducing energy consumption and improving vaccines long-term storage and immunity effects.
Patent Information
- Application Number
- CN202410968590.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-15
AI Technical Summary
Existing water-in-oil adjuvants in water cause damage to antigens during high-temperature emulsification, and have poor stability, prone to stratification and precipitation problems, resulting in high energy consumption and unstable product use.
Using low-temperature emulsification water-in-oil adjuvant, metabolable vegetable oil as base oil, and a variety of surfactants and immunoactive agents, the emulsification and long-term stability at low temperature are achieved through stirring and homogenization at room temperature. sex.
Under low temperature conditions, the emulsification of the water-in-oil delivery system is achieved, which reduces energy consumption, improves the long-term storage stability and immune effect of vaccines, and solves the problem of high-temperature emulsification destroys antigens.
Smart Images

Figure CN118949023A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of immunotechnology, and in particular relates to a low-temperature emulsified water-in-oil-in-water adjuvant, and a use method and application thereof. Background Art
[0002] Biphasic emulsion delivery systems can be divided into oil-in-water-in-oil (O / W / O) and water-in-oil-in-water (W / O / W). W / O / W is the most widely used in injectable drug delivery systems, and is more widely used in veterinary drugs, especially vaccine biological products. It is also called adjuvant when used in vaccine biological products. The most widely used veterinary vaccine in China is the French ISA206 water-in-oil-in-water adjuvant. In recent years, domestic generic products have also been launched but have failed to replace ISA206. Although water-in-oil-in-water adjuvants are widely used in China, they also have many defects. For example, the current adjuvants need to heat the adjuvant and antigen to 30-35℃ before emulsification, and then cool to 2-8℃ for storage. High-temperature emulsification is a serious destructive effect on the antigen, and the heating and cooling processes consume a lot of energy. As for stability, existing adjuvants often have problems with stratification and precipitation, which brings serious problems to the use of products. Summary of the invention
[0003] One of the purposes of the present invention is to provide a low-temperature emulsified water-in-oil-in-water adjuvant, wherein the water-in-oil-in-water adjuvant is any of the following adjuvants:
[0004] 1) Adjuvant 1: 24-28 parts of peanut oil for injection, 36-40 parts of soybean oil for injection, 6-10 parts of corn oil for injection, 1-3 parts of squalane, 0.5-1.5 parts of soybean lecithin for injection, 5-6 parts of Span 80, 1-2 parts of Span 85, 1-3 parts of Tween 20, 5-6 parts of Tween 80, 2-3 parts of mannitol monooleate, 0.5-1.5 parts of polyethylene glycol 2000, 0.5-1.5 parts of polyethylene glycol 4000, 1-2 parts of glycerol, 2-3 parts of ethanol, 0.2-1 parts of methanol, 0.02-0.07 parts of astragalus polysaccharide, 0.01-0.05 parts of isatis polysaccharide, 0.002-0.007 parts of immune polypeptide and 0.0001-0.0005 parts of CpG;
[0005] 2) Adjuvant 2: 28-32 parts of mineral oil CZS4, 28-32 parts of mineral oil KF50, 1-3 parts of squalene, 3-7 parts of vitamin E, 10-12 parts of Span 80, 17-19 parts of Span 85, 2-4 parts of polyethylene glycol 600 dioleate, 0.02-0.08 parts of astragalus polysaccharide, 0.03-0.08 parts of transfer factor and 0.003-0.008 parts of thymopentin.
[0006] Preferably, the amount of each component in 1) is as follows: 26 parts of peanut oil for injection, 38 parts of soybean oil for injection, 8 parts of corn oil for injection, 2 parts of squalane, 1 part of soybean lecithin for injection, 5.6 parts of Span 80, 1.8 parts of Span 85, 2 parts of Tween 20, 5.3 parts of Tween 80, 2.3 parts of mannitol monooleate, 1 part of polyethylene glycol 200, 1 part of polyethylene glycol 400, 1.2 parts of glycerol, 2.2 parts of ethanol, 0.6 parts of methanol, 0.05 parts of astragalus polysaccharide, 0.03 parts of isatis polysaccharide, 0.005 parts of immune polypeptide and 0.0003 parts of CpG.
[0007] Preferably, the amounts of the components in 2) are as follows: 30 parts of mineral oil CZS4, 30 parts of mineral oil KF50, 2 parts of squalene, 5 parts of vitamin E, 11 parts of Span 80, 18 parts of Span 85, 3 parts of polyethylene glycol 600 dioleate, 0.05 parts of astragalus polysaccharide, 0.05 parts of transfer factor and 0.005 parts of thymopentin.
[0008] More preferably, the preparation method of the adjuvant 1 in 1) is as follows:
[0009] (1) peanut oil for injection, soybean oil for injection, corn oil for injection, squalane, and soybean lecithin base oil composition for injection are sequentially added into a container and stirred at room temperature until clear;
[0010] (2) Add Span 80, Span 85, Tween 20, Tween 80, mannitol monooleate, polyethylene glycol 200, polyethylene glycol 400 surfactant composition, and glycerol, ethanol and methanol co-surfactants into another container in sequence, and stir until clear;
[0011] (3) Astragalus polysaccharide, Radix Isatidis polysaccharide, immune polypeptide and CpG immune active agent composition are dissolved in a third container filled with purified water, and then the base oil composition, surfactant composition and co-surfactant are simultaneously added to a fourth container under stirring at room temperature. After the addition is completed, stirring is continued at room temperature, and then the immune active agent composition is added, stirring is continued, and finally adjuvant 1 is obtained by homogenization.
[0012] More preferably, the preparation method of the adjuvant 2 in 2) is as follows:
[0013] (1) Add mineral oil CZS4, mineral oil KF50, squalene, and vitamin E base oil composition to a stirring tank in sequence, stir at room temperature until clear, and set aside;
[0014] (2) adding Span 80, Span 85 and polyethylene glycol 600 dioleate surfactant composition to another stirring container in sequence and stirring until clear;
[0015] (3) Add the astragalus polysaccharide, transfer factor and thymopentin immunostimulatory agent composition to a third container filled with purified water, and then simultaneously add the base oil composition and the surfactant composition to a fourth container under stirring at room temperature. After the addition is completed, continue stirring at room temperature, then add the immunostimulatory agent composition, continue stirring, and finally obtain adjuvant 2 by homogenization.
[0016] The second object of the present invention is to provide a method for using the low-temperature emulsified water-in-oil-in-water adjuvant, which comprises the following steps:
[0017] (1) First, the antigen is diluted with phosphate buffer, which is used as the aqueous phase;
[0018] (2) Weighing adjuvant 1 or adjuvant 2;
[0019] (3) The water phase and adjuvant 1 or adjuvant 2 are precooled in a water bath at 6°C ± 2°C. When the internal temperature of the water phase and the water-in-oil-in-water adjuvant reaches 8°C ± 2°C, emulsification begins to be performed to obtain a vaccine emulsion.
[0020] Preferably, the emulsification process in step (3) is as follows: stirring adjuvant 1 or adjuvant 2 at a speed of 300-400 rpm, slowly adding the aqueous phase, and continuously stirring for 20-30 minutes after the aqueous phase is added, while maintaining the temperature at 8°C±2°C.
[0021] The third object of the present invention is to provide the use of the above-mentioned low-temperature emulsified water-in-oil-in-water adjuvant in the preparation of animal vaccines.
[0022] Compared with the prior art, the present invention has the following beneficial effects:
[0023] The adjuvant 1 of the present invention uses metabolizable plant oil as the base oil, and is combined with a variety of surfactants and co-surfactants, thereby solving the problem that mineral oil cannot be metabolized. The water-in-oil-in-water (W / O / W) delivery system can be emulsified and used at low temperatures, thereby solving the problem of high temperature destroying antigens and reducing energy usage. The vaccine prepared using the delivery system can be stored for a long time at room temperature and 37°C, thereby solving the stability problem.
[0024] The second adjuvant of the present invention uses a water-in-oil-in-water biphasic adjuvant that can be emulsified at low temperature, and is compatible with a variety of surfactants and immunoactive agents, thereby solving a series of problems caused by high-temperature emulsification. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 This is the appearance of the ready-to-use vegetable oil water-in-oil-in-water adjuvant in Example 1.
[0026] Figure 2It is a comparison diagram of ISA206 and the vegetable oil biphasic adjuvant in Example 1, wherein A: the state of ISA206 adjuvant (a) and vegetable oil biphasic adjuvant (b) after adjuvant emulsification; B: microscopic observation of the vegetable oil biphasic adjuvant after emulsification (10X100); C: microscopic observation of ISA206 adjuvant after emulsification (10X100).
[0027] Figure 3 This is a particle size analysis diagram of the ISA206 adjuvant and vegetable oil biphasic adjuvant after emulsification in Example 1.
[0028] Figure 4 This is the conductivity analysis diagram of the ISA206 adjuvant and vegetable oil biphasic adjuvant emulsion in Example 1.
[0029] Figure 5 These are the results of centrifugal acceleration test analysis after emulsification of ISA206 adjuvant and vegetable oil biphasic adjuvant in Example 1, wherein A: ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C; B: ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C; C: vegetable oil biphasic adjuvant vaccine emulsified at 8°C±2°C.
[0030] Figure 6 The results of the high temperature acceleration test after emulsification of the ISA206 adjuvant and the vegetable oil biphasic adjuvant in Example 1 are shown, from left to right, in the state of 0 days, 1 day, 3 days and 7 days after emulsification in a 37°C environment. In each independent picture, the left side is the vegetable oil biphasic adjuvant vaccine emulsified at 8°C ± 2°C, the middle is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the right side is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C ± 2°C. The state on the first day showed that the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C showed obvious stratification, and the stratification gradually intensified on the 3rd and 7th days. The state on the 3rd day showed that the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C ± 2°C showed stratification, and the stratification was more obvious on the 7th day. There was no obvious stratification in the vegetable oil biphasic adjuvant vaccine emulsified at 8°C ± 2°C.
[0031] Figure 7The results of long-term stability analysis of the ISA206 adjuvant and the vegetable oil biphasic adjuvant emulsified in Example 1 are shown in the upper 4 pictures from left to right, respectively, after being placed in a 2-8°C environment for 0 days, 1 day, 3 days and 7 days, and the lower 4 pictures from left to right, respectively, after being placed in a 2-8°C environment for 15 days, 30 days, 90 days and 180 days. In each independent picture, the left side is the vegetable oil biphasic adjuvant vaccine emulsified at 8°C±2°C, the middle is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the right side is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C. On the 90th day, the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C was clearly stratified, and the stratification was more obvious at 180 days.
[0032] Figure 8 These are the results of the efficacy analysis of the ISA206 adjuvant and the vegetable oil biphasic adjuvant in Example 1 on the new bivalent inactivated vaccine (H9).
[0033] Fig. 9 These are the results of the efficacy analysis of the ISA206 adjuvant and the vegetable oil biphasic adjuvant in Example 1 on the new bivalent inactivated vaccine (ND).
[0034] Fig.10 This is the appearance of the low-temperature emulsified water-in-oil-in-water adjuvant (low-temperature emulsified biphasic adjuvant) in Example 2.
[0035] Fig.11 The ISA206 and low-temperature emulsified biphasic adjuvant in Example 2, wherein A: the state of the ISA206 adjuvant (a) and the low-temperature emulsified biphasic adjuvant (b) after adjuvant emulsification; B: microscopic observation of the low-temperature emulsified biphasic adjuvant after emulsification (10X100); C: microscopic observation of the ISA206 adjuvant after emulsification (10X100).
[0036] Fig.12 The particle size analysis results of the ISA206 adjuvant and the low-temperature emulsified biphasic adjuvant after emulsification in Example 2.
[0037] Fig.13 These are the results of the emulsion conductivity analysis of the ISA206 adjuvant and the low-temperature emulsified two-phase adjuvant in Example 2.
[0038] Fig.14 These are the results of centrifugal acceleration experiment analysis after emulsification of ISA206 adjuvant and low-temperature emulsified biphasic adjuvant in Example 2, where a: low-temperature emulsified biphasic adjuvant vaccine in this study; b: ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C; c: ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C.
[0039] Fig.15The results of the high temperature accelerated test analysis after emulsification of the ISA206 adjuvant and the low temperature emulsified biphasic adjuvant in Example 2 are shown, from left to right, in the state of 0 days, 1 day, 3 days and 7 days after emulsification in a 37°C environment. In each independent picture, the left side is the low temperature emulsified biphasic adjuvant vaccine of this study, the middle is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the right side is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C. On the first day, the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C and the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C showed obvious stratification, and the stratification gradually intensified on the 3rd and 7th days.
[0040] Fig.16 The results of long-term stability analysis of the ISA206 adjuvant and the low-temperature emulsified biphasic adjuvant after emulsification in Example 2, wherein the upper 4 pictures from left to right are the states of 0 days, 1 day, 3 days and 7 days after emulsification in a 2-8°C environment, and the lower 4 pictures from left to right are the states of 15 days, 30 days, 90 days and 180 days after emulsification in a 2-8°C environment. In each independent picture, the left side is the low-temperature emulsified biphasic adjuvant vaccine of this study, the middle is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the right side is the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C. On the 90th day, the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8°C±2°C was clearly stratified, and the stratification was more obvious at 180 days.
[0041] Fig.17 These are the results of the efficacy analysis of the ISA206 adjuvant and the low-temperature emulsified biphasic adjuvant in Example 2 on porcine circovirus type 2 subunit vaccine. DETAILED DESCRIPTION
[0042] The ISA206 mineral oil biphasic adjuvant used in the following examples was produced by SEPPIC, France.
[0043] Example 1
[0044] 1.1 Composition of water-in-oil-in-water (W / O / W) in this embodiment
[0045] 1.1.1 Base oil combination
[0046] Peanut oil for injection: 0, 1%, 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27%, 30%;
[0047] Soybean oil for injection: 0, 1%, 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27%, 30%;
[0048] Corn oil for injection: 0, 1%, 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27%, 30%;
[0049] Squalane: 0, 1%, 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27%, 30%;
[0050] Soybean lecithin for injection: 0, 1%, 3%, 6%, 9%, 12%, 15%.
[0051] 1.1.2 Surfactant Combinations
[0052] Span 80: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0053] Span 85: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0054] Tween 20: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0055] Tween 80: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0056] Mannitol monooleate: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0057] Polyethylene glycol 200: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%;
[0058] Polyethylene glycol 400: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%.
[0059] 1.1.3 Cosurfactant
[0060] Glycerol: 0%, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%;
[0061] Ethanol: 0%, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%;
[0062] Methanol: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%.
[0063] 1.1.4 Immunoactive Agents
[0064] Astragalus polysaccharide: 0, 0.2%, 0.4%, 0.6%, 0.8%, 1%;
[0065] Radix Isatidis polysaccharides: 0, 0.2%, 0.4%, 0.6%, 0.8%, 1%;
[0066] Immune peptide: 0, 0.02%, 0.04%, 0.06%, 0.08%, 0.1%;
[0067] CpG: 0, 0.002%, 0.004%, 0.006%, 0.008%, 0.01%.
[0068] 1.2 Specific process flow
[0069] Into a stirring tank, 26kg of peanut oil for injection, 38kg of soybean oil for injection, 8kg of corn oil for injection, 2kg of squalane, and 1kg of soybean lecithin for injection were added in sequence, and stirred at 150 revolutions per minute for 30 minutes at room temperature until clarified, and then set aside. Similarly, into another stirring tank, 5.6kg of Span 80, 1.8kg of Span 85, 2kg of Tween 20, 5.3kg of Tween 80, 2.3kg of mannitol monooleate, 1kg of polyethylene glycol 200, 1kg of polyethylene glycol 400 surfactant composition, and 1.2kg of glycerol, 2.2kg of ethanol, and 0.6kg of methanol cosurfactant were added in sequence, and stirred at 150 revolutions per minute for 30 minutes until clarified. Weigh 0.05 kg of Astragalus polysaccharide (article number SA9790, Beijing Solaibao Technology Co., Ltd.), 0.03 kg of Radix Isatidis polysaccharide (article number: S27807, Shanghai Yuanye Biotechnology Co., Ltd.), 0.005 kg of Thymopentin (article number: B21401, Shanghai Yuanye Biotechnology Co., Ltd.) and 0.0003 kg of CpG immunoactive agent composition and dissolve them in 1.9147 kg of purified water. At room temperature and a speed of 150 revolutions per minute, add the above base oil composition, surfactant composition and co-surfactant to the third stirring tank simultaneously, ensure that the oil and surfactant and co-surfactant are added simultaneously, continue stirring at room temperature at a speed of 150 revolutions per minute for 30 minutes after the addition is completed, then add the immunoactive agent composition and stir at a speed of 150 revolutions per minute for 30 minutes, finally homogenize by a high pressure homogenizer at a pressure of not less than 1000 bar to obtain the finished product, and the obtained product is a ready-to-use vegetable oil water-in-oil-in-water adjuvant.
[0070] 2.1 Physical and chemical parameter tests, emulsification tests and animal immunity tests
[0071] 2.1.1 Characteristic test
[0072] Raw materials from different manufacturers and brands were selected to prepare different batches of adjuvants for physical and chemical parameter analysis.
[0073] (1) Visual inspection: Observe the color and appearance of the adjuvant.
[0074] (2) Physical and chemical parameter testing: Acid value, hydroxyl value, iodine value, peroxide value and saponification value shall be determined according to the acid value test method in Part 0713 of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine. The acid value, hydroxyl value, iodine value, peroxide value and saponification value shall be determined according to Part 1 of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine, 0841 Residue on Ignition Test Method. The acid value shall be determined according to Part 1 of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine, 0821 Heavy Metal Test Method. The pH value of the adjuvant shall also be tested.
[0075] 2.1.2 Observation of state after emulsification
[0076] (1) Status Observation
[0077] The vegetable oil two-phase emulsification process used in this embodiment is a one-step emulsification method. First, the antigen (Newcastle disease LaSota and avian influenza H9 bivalent inactivated vaccine) is diluted once with a phosphate buffer solution, pH 7.5-8.0, and used as the aqueous phase. Then, the aqueous phase and the ready-to-use vegetable oil water-in-oil-in-water adjuvant of equal mass are weighed and precooled in a 6°C±2°C water bath. When the internal temperature of the aqueous phase and the ready-to-use vegetable oil water-in-oil-in-water adjuvant reaches 8°C±2°C, emulsification begins. The emulsification process is: the ready-to-use vegetable oil water-in-oil-in-water adjuvant is stirred at a speed of 350rpm, and the aqueous phase is slowly added at this time. During the process of adding the aqueous phase, there may be phenomena such as viscosity changes. After the aqueous phase is added, stirring is continued for 20-30min, and the temperature is maintained at 8°C±2°C.
[0078] Emulsification of ISA206 mineral oil biphasic adjuvant at 30-35℃: First weigh the same mass of water phase and ISA206, and preheat them in 30-35℃ water for about 15 minutes. Stir ISA206 at 300rpm, then slowly add the water phase, continue stirring for 20-30min after the water phase is added, keep the temperature at 30℃-35℃, and immediately put it in a 6℃±2℃ water bath to cool down after emulsification.
[0079] Observe the color of the emulsified solution, whether the particles are a uniform suspension, whether there is precipitation, clots, stratification, or other foreign matter. Observe the state of the solution particles under a microscope, and use a laser particle size analyzer to detect the particle size of the emulsion.
[0080] (2) Conductivity of the emulsification process
[0081] Weigh 20g of ready-to-use vegetable oil biphasic adjuvant (oil phase) and 100g of water phase (pH7.5-8.0) respectively, and then put them into a 6℃±2℃ water bath for precooling. When the internal temperature of the water phase and the oil phase reaches 8℃±2℃, start emulsification and detect the change in conductivity. First, add 10% of the mass of oil each time, detect the conductivity of the mixed solution each time, and record the conductivity detection value. After 100% of the oil phase is added, add 50% of the mass of the oil phase each time, measure the conductivity of the mixed solution, record the conductivity detection value, and then draw a curve chart of conductivity and the proportion of added water phase.
[0082] The emulsion conductivity of ISA206 mineral oil biphasic adjuvant at 30-35°C was tested in the same way.
[0083] (3) Vaccine dosage form stability test
[0084] The dosage form stability test includes an accelerated test and a long-term test, wherein the accelerated test includes a centrifugation and high temperature test. The ready-to-use vegetable oil biphasic adjuvant and the ISA206 mineral oil biphasic adjuvant in this embodiment are subjected to the low-temperature emulsification method in the state observation experiment (1). In addition, the ISA206 mineral oil biphasic adjuvant is emulsified at 30-35°C: first weigh the water phase and the oil phase of equal mass, preheat them in a 30-35°C water bath for about 15 minutes, stir the oil phase at 300 rpm, then slowly add the water phase, continue stirring for 20-30 minutes after the water phase is added, and keep the temperature at 30°C-35°C. After the emulsification is completed, immediately place it in a 6°C±2°C water bath to cool down.
[0085] ① Centrifugal acceleration test: Take 8℃±2℃ emulsified vegetable oil biphasic vaccine, ISA206 mineral oil biphasic adjuvant vaccine, and ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃, put 5 ml of each into a 10 ml centrifuge tube, centrifuge at 3000rpm for 15min, and observe whether there is stratification or oil phase precipitation.
[0086] ②37℃ environmental accelerated test: Take 8℃±2℃ emulsified vegetable oil biphasic and ISA206 mineral oil biphasic adjuvant vaccines, as well as 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, 10 ml each, put into a vial, put into a 37℃ constant temperature box, and observe the status of the vaccine at 0 day, 1 day, 3 days and 7 days respectively.
[0087] ③2-8℃ status observation test: Take 8℃±2℃ emulsified vegetable oil biphasic and ISA206 mineral oil biphasic adjuvant vaccines, as well as 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, 10 ml each, put into a vial, put into a 2-8℃ refrigerator, and observe the vaccine status at 0 day, 1 day, 3 days, 7 days, 15 days, 30 days, 90 days and 180 days respectively.
[0088] 2.1.3 Animal Immunization Test
[0089] (1) Safety test
[0090] Vaccine preparation: The vaccine was prepared according to the vaccine emulsification method in (3) vaccine dosage form stability test, using Newcastle disease LaSota and avian influenza H9 bivalent inactivated vaccines as models.
[0091] The experiment was divided into two groups, a control group and an experimental group. The control group was immunized with the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the experimental group was immunized with the vegetable oil biphasic vaccine emulsified at 8°C±2°C in this embodiment. Each group was 1000 7-day-old white-feathered broilers, and the immunization dose of the white-feathered broilers was 0.3 ml / bird. The safety experiment immunized with 3 times the dose, and the immunization site was subcutaneous in the neck. After immunization, the clinical manifestations of the chickens, such as feeding, defecation, fur, mental state and death, were observed.
[0092] (2) Efficacy test
[0093] Vaccine preparation: Prepare the vaccine according to the vaccine emulsification method in (3) vaccine dosage form stability test, using the new influenza bivalent inactivated vaccine as a model.
[0094] The experiment was divided into two groups, a control group and an experimental group. The control group was immunized with the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the experimental group was immunized with the vegetable oil biphasic adjuvant vaccine emulsified at 8°C±2°C in this embodiment. 1000 7-day-old white-feathered broilers were immunized with an immunization dosage of 0.3 ml / bird, and the immunization site was subcutaneous on the back of the neck. The antibody levels were detected before immunization, 14 days, 21 days, 28 days and 35 days after immunization, respectively. 20 birds were randomly selected from each group for blood collection, serum separation, and serum antibody detection.
[0095] 3.1 Experimental results and discussion
[0096] 3.1.1 Characteristic test
[0097] (1) Visual inspection
[0098] The one-step ready-to-use vegetable oil-water-in-oil adjuvant has a light yellow, clear, transparent liquid appearance, a certain viscosity, and no stratification. Compared with ISA206, the ready-to-use vegetable oil-water-in-oil adjuvant prepared in this example is darker in color. Figure 1 .
[0099] (2) Physical and chemical parameter inspection
[0100] Table 1 shows the results of physical and chemical parameter analysis of different batches of adjuvants, with acid value of 0.3-0.8 mg / g, hydroxyl value of 40-70 mg / g, iodine value of 5-11 g / 100 g, peroxide value of 4-9 mmol / kg, saponification value of 150-210 mg / g, residue on ignition less than 0.5%, heavy metal less than 10 parts per million, and pH 7-8.
[0101] Table 1 Physicochemical parameters of ready-to-use vegetable oil-in-water adjuvant
[0102] Inspection items Test results Acid value 0.3-0.8mg / g Hydroxyl value 40-70mg / g Iodine value 5-11g / 100g Peroxide value 4-9mmol / kg Saponification value 150-210mg / g Ignition residue Less than 0.5% heavy metal Less than 10 parts per million pH 7-8
[0103] 3.1.2 Observation of state after emulsification
[0104] (1) Status Observation
[0105] The ready-to-use vegetable oil water-in-oil-in-water adjuvant is emulsified into a milky white suspension emulsion with uniform particles, no precipitation, no stratification, and no other foreign matter. There is no significant difference compared with ISA206 ( Figure 2 A). However, microscopic observations showed that ISA206 particles were not uniform ( Figure 2 B and 2C).
[0106] Through the particle size analysis of the emulsion ( Figure 3 ), the particle size of the ready-to-use vegetable oil-water-in-oil-water adjuvant after emulsification is uniform, with only a single peak, while the particle size of the ISA206 adjuvant after emulsification is non-uniform, with multiple peaks. From the peak of the particle size, the average particle size of the ready-to-use vegetable oil-water-in-oil-water adjuvant after emulsification is around 225.6nm, close to the nanometer level and a submicron adjuvant. The maximum particle sizes of the ISA206 adjuvant after emulsification are 350.1nm and 1850.3nm, respectively, belonging to a micron adjuvant.
[0107] (2) Conductivity of the emulsification process
[0108] The emulsification process of the ready-to-use vegetable oil water-in-oil-in-water adjuvant showed no conductivity before 100% was added, and the conductivity increased directly after the addition (see Figure 4 ).
[0109] (3) Vaccine dosage form stability test
[0110] ① Centrifugal acceleration test: observe after centrifugation of the vegetable oil biphasic adjuvant vaccine and ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8℃±2℃, and the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃. Figure 5, the vegetable oil biphasic vaccine emulsified at 8℃±2℃ showed no stratification or precipitation by naked eye observation, while the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8℃±2℃ showed more than 30% stratification after centrifugation, and the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃ showed a slight separation at the bottom. This indicates that the stability of the low-temperature emulsified ISA206 mineral oil biphasic adjuvant is poor and does not meet the requirements of practical applications.
[0111] ②37℃ environmental accelerated test: observe after centrifugation of the plant oil biphasic adjuvant vaccine and ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8℃±2℃, and the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃. The ISA206 mineral oil biphasic adjuvant, whether emulsified at 8℃±2℃ or 30-35℃, began to show obvious stratification in the 37℃ environment after 0.5 days, while the plant oil biphasic vaccine emulsified at 8℃±2℃ showed stratification until 7 days (see Figure 6 ). This indicates that the stability of the emulsified vegetable oil biphasic adjuvant is better than that of the ISA206 mineral oil biphasic adjuvant.
[0112] ③2-8℃ state observation test: The plant oil biphasic adjuvant vaccine and ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8℃±2℃, and the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃ were observed after centrifugation. Placed in a 2-8℃ refrigerator, the vaccine status was observed at 1 day, 3 days, 7 days, 14 days, 30 days, 90 days and 180 days. The plant oil biphasic adjuvant vaccine emulsified at 8℃±2℃ and the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃ showed no obvious stratification or precipitation. This shows that the vaccine stability of the two emulsification methods meets the requirements of practical applications. However, the low-temperature emulsified ISA206 mineral oil biphasic adjuvant showed obvious stratification on the third day, indicating that the stability of the low-temperature ISA206 adjuvant is poor (see Figure 7 ), which does not meet the actual application requirements.
[0113] 3.1.3 Animal Immunization Test Results
[0114] (1) Safety test
[0115] According to the safety test results, the ISA206 group had a slightly lower feed intake immediately after immunization compared with the low-temperature emulsified vegetable oil adjuvant, and there was no significant difference in defecation, fur, mental state, and death, indicating that both the ISA206 group and the low-temperature emulsified vegetable oil adjuvant had good safety.
[0116] (2) Efficacy test
[0117] After animal immunization, serum is collected to detect antibody levels. Figure 8The results showed that there was no difference in H9 antibody levels on the 14th day after immunization, but on the 21st, 28th and 35th days after immunization, the antibody level of the vegetable oil adjuvant was significantly higher than that of the ISA206 adjuvant by more than 1 titer, and even more than 2 titers higher on the 28th day. Fig. 9 The results showed that the ND antibody level showed a significant difference on the 14th day after immunization, with the vegetable oil adjuvant group being about 1 titer higher than the ISA206 adjuvant. Similarly, on the 21st, 28th and 35th days after immunization, the antibody level of the vegetable oil adjuvant was significantly higher than that of the ISA206 adjuvant by more than 1 titer. From the perspective of animal serum antibodies after immunization, the vegetable oil adjuvant is significantly better than the ISA206 adjuvant.
[0118] 4 Conclusion
[0119] The vegetable oil biphasic adjuvant prepared in this embodiment exhibits superior properties, and uses vegetable oil as a base oil to achieve oil metabolizability. Compared with ISA206, the vegetable oil biphasic adjuvant in this study achieves low-temperature emulsification, reducing the cost of vaccine production. In addition, the effect is improved after adding an immune activator.
[0120] Example 2
[0121] 1.1 Composition of water-in-oil-in-water (W / O / W) in this embodiment
[0122] 1.1.1 Base oil combination
[0123] The invention comprises at least one of mineral oil CZS4, mineral oil KF50, vitamin E and squalene.
[0124] 1.1.2 Surfactant Combinations
[0125] The invention comprises at least one of Span 80, Tween 85 and polyethylene glycol 600 dioleate.
[0126] 1.1.3 Immunoactive Agents
[0127] At least one of transfer factor, bursa-tripeptide, and thymopentin.
[0128] 1.2 Ratios of the components in the water-in-oil-in-water (W / O / W) solution in this embodiment
[0129] 1.2.1 Base oil combination
[0130] Mineral oil CZS4: 0, 1%, 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27%, 30%;
[0131] Mineral oil KF50: 0, 1%, 3%, 6%, 9%, 12%, 15%, 18%, 21%, 24%, 27%, 30%;
[0132] Squalene: 0, 1%, 3%, 6%, 9%, 12%;
[0133] Vitamin E: 0, 1%, 3%, 6%, 9%, 12%.
[0134] 1.2.2 Surfactant Combinations
[0135] Span 80: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0136] Tween 85: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%;
[0137] Polyethylene glycol 600 dioleate: 0, 1%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%.
[0138] 1.2.3 Immunoactive Agents
[0139] Astragalus polysaccharide: 0, 0.2%, 0.4%, 0.6%, 0.8%, 1%;
[0140] Transfer factor: 0, 0.2%, 0.4%, 0.6%, 0.8%, 1%;
[0141] Thymopentin: 0, 0.002%, 0.004%, 0.006%, 0.008%, 0.01%.
[0142] 1.2 Process flow
[0143] Add 30kg of mineral oil CZS4 (model: CZS4, Zhejiang Zhengxin Petroleum Technology Co., Ltd.), 30kg of mineral oil KF50 (Korea Ruizhen KF50 model white oil), 2kg of squalene, and 5kg of vitamin E base oil combination to the stirring tank, stir at room temperature at a speed of 150 revolutions per minute for 30 minutes until clear, and set aside. Similarly, add 11kg of Span 80, 18kg of Span 85, and 3kg of polyethylene glycol 600 dioleate surfactant composition to another stirring tank, and stir at a speed of 150 revolutions per minute for 30 minutes until clear. Weigh 0.05kg of astragalus polysaccharide (article number: SA9790, Beijing Solaibao Technology Co., Ltd.), 0.05kg of transfer factor (a drug produced by Xi'an Jinhua Pharmaceutical Factory of Jinhua Enterprise (Group) Co., Ltd.) and 0.005kg of thymopentin (article number: B21401, Shanghai Yuanye Biotechnology Co., Ltd.) Immunoactive agent composition is dissolved in 0.895kg of purified water. At room temperature, the base oil composition and the surfactant composition are simultaneously added to the third stirring tank at a speed of 150 revolutions per minute to ensure that the oil and the surfactant are added simultaneously. After the addition is completed, the mixture is stirred at room temperature at a speed of 150 revolutions per minute for 30 minutes, and then the immunoactive agent composition is added and stirred at a speed of 150 revolutions per minute for 30 minutes. Finally, the finished product is obtained by homogenizing with a high-pressure homogenizer at a pressure of not less than 1000 bar. The resulting product is a ready-to-use low-temperature emulsified water-in-oil-in-water adjuvant.
[0144] 2.1 Physical and chemical parameter tests, emulsification tests and animal immunity tests
[0145] 2.1.1 Characteristic test
[0146] Raw materials from different manufacturers and brands were selected to prepare different batches of adjuvants for physicochemical parameter analysis.
[0147] (1) Visual inspection: Observe the color and appearance of the adjuvant.
[0148] (2) Physical and chemical parameter testing: Acid value, hydroxyl value, iodine value, peroxide value and saponification value shall be determined according to the acid value test method in Part 0713 of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine. The acid value, hydroxyl value, iodine value, peroxide value and saponification value shall be determined according to Part 1 of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine, 0841 Residue on Ignition Test Method. The acid value shall be determined according to Part 1 of the 2020 edition of the Chinese Pharmacopoeia of Veterinary Medicine, 0821 Heavy Metal Test Method. The pH value of the adjuvant shall also be tested.
[0149] 2.1.2 Observation of state after emulsification
[0150] (1) Status Observation
[0151] The low-temperature emulsified biphasic adjuvant process used in this embodiment is a one-step emulsification method. First, prepare the water phase: dilute the porcine circovirus type 2 subunit antigen Cap protein (Liu Panrao. Soluble expression and immune characteristics of porcine circovirus type 2 Cap gene in Escherichia coli [D]. Nanjing Agricultural University, 2016. DOI: CNKI: CDMD: 2.1017.261948.) with phosphate buffer to 10ug / ml, pH7.5-8.0, then weigh the same mass of water phase and oil phase and precool them in a 6℃±2℃ water bath, and start emulsification when the internal temperature of the water phase and oil phase reaches 8℃±2℃. Emulsification process: Stir the oil phase at a speed of 500rpm, then slowly add the water phase. There may be viscosity changes during the addition of the water phase. After the water phase is added, continue stirring for 20-30min and keep the temperature at 8℃±2℃.
[0152] ISA206 mineral oil biphasic adjuvant is emulsified at 30-35°C: first weigh the same mass of water phase (water phase) and oil phase, and preheat them in 30-35°C water for about 15 minutes. Stir the oil phase at 300rpm, and then slowly add the water phase. After the water phase is added, continue stirring for 20-30 minutes, keep the temperature at 30℃-35℃, and immediately put it in a 6℃±2℃ water bath to cool down after emulsification.
[0153] Observe the color of the emulsified solution, whether the particles are a uniform suspension, whether there is precipitation, clots, stratification, or other foreign matter. Use a laser particle size analyzer to detect the particle size of the emulsion.
[0154] (2) Conductivity of the emulsification process
[0155] Weigh 20g of low-temperature emulsified biphasic adjuvant and 100g of aqueous phase (pH7.5-8.0), then precool in a 6℃±2℃ water bath. When the internal temperature of the aqueous phase and the oil phase reaches 8℃±2℃, start emulsification and detect conductivity changes. First, add 10% of the oil mass each time, detect the conductivity of the mixed solution each time, and record the conductivity detection value. After 100% of the oil phase is added, add 50% of the oil phase mass each time, measure the conductivity of the mixed solution, and record the conductivity detection value. Then draw a curve chart of conductivity and the proportion of added aqueous phase.
[0156] The emulsion conductivity of ISA206 mineral oil biphasic adjuvant at 30-35°C was tested in the same way.
[0157] (3) Vaccine dosage form stability test
[0158] The dosage form stability test includes an accelerated test and a long-term test, wherein the accelerated test includes a centrifugation and high temperature test. The low-temperature emulsified biphasic adjuvant and the ISA206 mineral oil biphasic adjuvant in this embodiment are subjected to the low-temperature emulsification method in the state observation experiment (1). In addition, the ISA206 mineral oil biphasic adjuvant is emulsified at 30-35°C: first weigh the water phase and the oil phase of equal mass, and preheat them in a 30-35°C water area for about 15 minutes. Stir the oil phase at a speed of 300 rpm, and then slowly add the water phase. After the water phase is added, continue stirring for 20-30 minutes, keeping the temperature at 30°C-35°C, and immediately place it in a 6°C±2°C water bath to cool down after the emulsification is completed.
[0159] ① Centrifugal acceleration test: Take 5 ml of low-temperature emulsified biphasic adjuvant vaccine, 8℃±2℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, and 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, respectively, and place them in a 10 ml centrifuge tube, and centrifuge at 3000 rpm for 15 minutes. Observe for stratification or oil phase precipitation.
[0160] ②37℃ environmental accelerated test: Take 10ml of low-temperature emulsified biphasic adjuvant vaccine, 8℃±2℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, and 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, and put them into a vial. Put them in a 37℃ constant temperature box and observe the status of the vaccine on 0, 1, 3 and 7 days.
[0161] ③2-8℃ status observation test: Take 10ml of low-temperature emulsified biphasic adjuvant vaccine, 8℃±2℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, and 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine, and put them into a vial. Put them in a 2-8℃ refrigerator and observe the status of the vaccine at 0 days, 1 day, 3 days, 7 days, 14 days, 30 days, 90 days and 180 days.
[0162] 2.1.3 Animal Immunization Test
[0163] (1) Safety test
[0164] Vaccine preparation: The vaccine was prepared according to the vaccine emulsification method in (3) vaccine dosage form stability test, and the aqueous phase was 10ug / ml porcine circovirus type 2 subunit antigen phosphate buffer.
[0165] The experiment was divided into two groups, a control group and an experimental group. The control group was immunized with a 30-35°C emulsified ISA206 mineral oil biphasic adjuvant vaccine, and the experimental group was immunized with a low-temperature emulsified biphasic adjuvant vaccine in this embodiment. Each group consisted of 50 21-day-old piglets, with a piglet immunization dose of 1 ml / pig. The safety experiment immunized with a 3-fold dose, and the immunization site was the neck and back muscles. After immunization, the clinical manifestations of the piglets, such as feeding, defecation, fur, mental state, body temperature, and death, were observed.
[0166] (2) Efficacy test
[0167] Vaccine preparation: Prepare the vaccine according to the vaccine emulsification method in (3) Vaccine dosage form stability test, using porcine circovirus type 2 subunit vaccine as a model. Aqueous phase: Dilute porcine circovirus type 2 subunit antigen to 10ug / ml with phosphate buffer, pH 7.5-8.0.
[0168] The experiment was divided into two groups, a control group and an experimental group. The control group was immunized with the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35°C, and the experimental group was immunized with the low-temperature emulsified biphasic adjuvant vaccine in this study. Each group consisted of 50 21-day-old piglets, with an immunization dose of 1 ml per piglet, and the immunization site was the neck and back muscles. Antibody levels were tested before immunization, 14 days, 21 days, 28 days, and 35 days after immunization. 20 pigs were randomly selected from each group for blood collection, serum separation, and serum antibody testing.
[0169] 3.1 Experimental results and discussion
[0170] 3.1.1 Characteristic test
[0171] (1) Visual inspection
[0172] The appearance of the one-step low-temperature emulsified water-in-oil-in-water biphasic adjuvant is a light yellow clear transparent liquid with a certain viscosity and no stratification. Compared with ISA206, the color of the ready-to-use vegetable oil water-in-oil-in-water adjuvant in this study is darker, such as Fig.10 .
[0173] (2) Physical and chemical parameter inspection
[0174] Table 2 shows the results of physical and chemical parameter analysis of different batches of adjuvants, acid value is 0.2-0.5 mg / g, hydroxyl value is 11-20 mg / g, iodine value is 0.3-0.8 g / 100 g, peroxide value is 1.5-3.5 mmol / kg, saponification value is 15-30 mg / g, ignition residue is less than 0.5%, heavy metal is less than 10 parts per million, pH is 7-8.
[0175] Table 2 Physicochemical parameters of low temperature emulsified biphasic adjuvant and ISA206 in this example
[0176] Inspection items The low temperature emulsification two-phase detection value in this study ISA206 test value Acid value 0.2-0.5mg / g 0.14mg / g Hydroxyl value 11-20mg / g 11.3mg / g Iodine value 0.3-0.8g / 100g 0.96g / 100g Peroxide value 1.5-3.5mmol / kg 0.3mmol / kg Saponification value 15-30mg / g 20.57mg / g Ignition residue Less than 0.5% Less than 0.5% heavy metal Less than 10 parts per million Less than 10 parts per million pH 7-8 6.85
[0177] 3.1.2 Observation of state after emulsification
[0178] (1) Status Observation
[0179] After low-temperature emulsification of water-in-oil-in-water adjuvant, the solution was light milky white, with uniform particles, no precipitation, no stratification, and no other foreign matter. Compared with ISA206, it was light milky white (11A). However, the results of microscopic observation showed that ISA206 had uneven particles ( Fig.11 B and 11C).
[0180] Through the particle size detection and analysis of the emulsion, the particle size of the low-temperature emulsified water-in-oil-in-water biphasic adjuvant after emulsification is uniform, with only a single peak, while the particle size of the ISA206 adjuvant after emulsification is non-uniform, with multiple peaks. From the peak of the particle size, the average particle size of the low-temperature emulsified water-in-oil-in-water biphasic adjuvant after emulsification is 99.8nm, which is a nano-level adjuvant. The average particle sizes of the ISA206 adjuvant after emulsification are 380.0nm and 1976.6nm, respectively, which belong to the micron-level adjuvant, see Fig.12 .
[0181] (2) Conductivity of the emulsification process
[0182] The low-temperature emulsification of water-in-oil-in-water biphasic adjuvants showed that there was no conductivity before the addition of 60% water phase. The conductivity increased directly after the addition and gradually leveled off with the addition of water phase. Fig.13 .
[0183] (3) Vaccine dosage form stability test
[0184] ① Centrifugal acceleration test: observe after centrifugation of low-temperature emulsified biphasic adjuvant vaccine, ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8℃±2℃, and ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃. In this study, the low-temperature emulsified biphasic adjuvant vaccine showed no stratification or precipitation by naked eye observation. However, after centrifugation, the ISA206 mineral oil biphasic adjuvant vaccine emulsified at 8℃±2℃ showed obvious stratification of more than 30%. The ISA206 mineral oil biphasic adjuvant vaccine emulsified at 30-35℃ showed slight stratification at the bottom, see Fig.14 .
[0185] This indicates that the low-temperature emulsified ISA206 mineral oil biphasic adjuvant has poor stability and may not meet the requirements of practical applications.
[0186] ②37℃ environmental accelerated test: low temperature emulsified biphasic adjuvant vaccine and ISA206 biphasic adjuvant vaccine emulsified at 8℃±2℃, and ISA206 biphasic adjuvant vaccine emulsified at 30-35℃ were centrifuged and observed. ISA206 biphasic adjuvant, whether emulsified at 8℃±2℃ or 30-35℃, began to show obvious stratification in 37℃ environment after 1 day, while the low temperature emulsified biphasic adjuvant vaccine in this study did not stratify until 7 days, see Fig.15 This indicates that the stability of low-temperature emulsified biphasic adjuvant is better than that of ISA206 mineral oil biphasic adjuvant.
[0187] ③2-8℃ state observation test: low-temperature emulsified biphasic adjuvant vaccine and 8℃±2℃ ISA206 biphasic adjuvant vaccine, as well as 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine were observed after centrifugation. Placed in a 2-8℃ refrigerator, the vaccine status was observed at 1 day, 3 days, 7 days, 14 days, 30 days, 90 days and 180 days. Among them, the low-temperature emulsified biphasic adjuvant vaccine and the 30-35℃ emulsified ISA206 mineral oil biphasic adjuvant vaccine in this study did not show obvious stratification or precipitation. This shows that the vaccine stability of the two emulsification methods meets the requirements of practical applications. However, the ISA206 mineral oil biphasic adjuvant emulsified at 8℃±2℃ showed obvious stratification on the third day, indicating that the stability of the low-temperature ISA206 adjuvant is poor, see Fig.16 , which does not meet the actual application requirements.
[0188] 3.1.3 Animal Immunization Test Results
[0189] (1) Safety test
[0190] According to the results of the safety experiment, the ISA206 group that was immunized with 3 times the dose and emulsified at 30-35℃ showed a slight decrease in food intake after immunization, and then returned to normal 24 hours later, compared with the low-temperature emulsified biphasic adjuvant of this study. However, some of the ISA206 group emulsified at 30-35℃ became listless and lay down after immunization. There were no significant differences in defecation, fur, body temperature, etc., and there were no deaths. This shows that both the ISA206 group and the low-temperature emulsified biphasic adjuvant of this study have good safety, but the low-temperature emulsified biphasic adjuvant of this study showed higher safety.
[0191] (2) Efficacy test
[0192] After the animals are immunized, serum is collected and the antibody level is tested after the serum is diluted 3000 times. Fig.17 The antibody showed that the antibody level of low-temperature emulsified biphasic adjuvant was significantly higher than that of ISA206 adjuvant on the 14th day, 21st day, 28th day and 35th day after immunization. From the perspective of serum antibodies of animals after immunization, the low-temperature emulsified biphasic adjuvant in this study was significantly better than ISA206 biphasic adjuvant.
[0193] 4 Conclusion
[0194] The low-temperature biphasic adjuvant prepared in this example exhibits superior properties, especially low-temperature emulsification, and is significantly superior to ISA206 adjuvant in terms of production process and production cost. In addition, the low-temperature biphasic adjuvant in this study has better immune effect than ISA206 adjuvant. The low-temperature biphasic adjuvant in this study solves key problems in the veterinary field.
[0195] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A low-temperature emulsified water-in-oil-in-water adjuvant, characterized in that: The water-in-oil-in-water adjuvant is any of the following adjuvants: 1) Adjuvant 1: 24-28 parts of peanut oil for injection, 36-40 parts of soybean oil for injection, 6-10 parts of corn oil for injection, 1-3 parts of squalane, 0.5-1.5 parts of soybean lecithin for injection, 5-6 parts of Span 80, 1-2 parts of Span 85, 1-3 parts of Tween 20, 1-6 parts of Tween 805, 2-3 parts of mannitol monooleate, 0.5-1.5 parts of polyethylene glycol 2000, 0.5-1.5 parts of polyethylene glycol 4000, 1-2 parts of glycerol, 2-3 parts of ethanol, 0.2-1 parts of methanol, 0.02-0.07 parts of astragalus polysaccharide, 0.01-0.05 parts of isatis polysaccharide, 0.002-0.007 parts of immune polypeptide and 0.0001-0.0005 parts of CpG; 2) Adjuvant 2: 28-32 parts of mineral oil CZS4, 28-32 parts of mineral oil KF50, 1-3 parts of squalene, 3-7 parts of vitamin E, 10-12 parts of Span 80, 17-19 parts of Span 85, 2-4 parts of polyethylene glycol 600 dioleate, 0.02-0.08 parts of astragalus polysaccharide, 0.03-0.08 parts of transfer factor and 0.003-0.008 parts of thymopentin.
2. The low-temperature emulsified water-in-oil-in-water adjuvant according to claim 1, characterized in that: The dosage of each component in 1) is as follows: 26 parts of peanut oil for injection, 38 parts of soybean oil for injection, 8 parts of corn oil for injection, 2 parts of squalane, 1 part of soybean lecithin for injection, 5.6 parts of Span 80, 1.8 parts of Span 85, 2 parts of Tween 20, 5.3 parts of Tween 80, 2.3 parts of mannitol monooleate, 1 part of polyethylene glycol 200, 1 part of polyethylene glycol 400, 1.2 parts of glycerol, 2.2 parts of ethanol, 0.6 parts of methanol, 0.05 parts of astragalus polysaccharide, 0.03 parts of isatis polysaccharide, 0.005 parts of immune polypeptide and 0.0003 parts of CpG.
3. The low-temperature emulsified water-in-oil-in-water adjuvant according to claim 1, characterized in that: The amounts of the components in 2) are as follows: 30 parts of mineral oil CZS4, 30 parts of mineral oil KF50, 2 parts of squalene, 5 parts of vitamin E, 11 parts of Span 80, 18 parts of Span 85, 3 parts of polyethylene glycol 600 dioleate, 0.05 parts of astragalus polysaccharide, 0.05 parts of transfer factor and 0.005 parts of thymopentin.
4. The low-temperature emulsified water-in-oil-in-water adjuvant according to any one of claims 1 to 3, characterized in that: The preparation method of adjuvant 1) is as follows: (1) peanut oil for injection, soybean oil for injection, corn oil for injection, squalane, and soybean lecithin base oil composition for injection are sequentially added into a container and stirred at room temperature until clear; (2) Add Span 80, Span 85, Tween 20, Tween 80, mannitol monooleate, polyethylene glycol 200, polyethylene glycol 400 surfactant composition, and glycerol, ethanol and methanol co-surfactants into another container in sequence, and stir until clear; (3) Astragalus polysaccharide, Radix Isatidis polysaccharide, immune polypeptide and CpG immune active agent composition are dissolved in a third container filled with purified water, and then the base oil composition, surfactant composition and co-surfactant are simultaneously added to a fourth container under stirring at room temperature. After the addition is completed, stirring is continued at room temperature, and then the immune active agent composition is added, stirring is continued, and finally adjuvant 1 is obtained by homogenization.
5. The low-temperature emulsified water-in-oil-in-water adjuvant according to any one of claims 1 to 3, characterized in that: The preparation method of adjuvant 2 in 2) is as follows: (1) Add mineral oil CZS4, mineral oil KF50, squalene, and vitamin E base oil composition to a stirring tank in sequence, stir at room temperature until clear, and set aside; (2) adding Span 80, Span 85 and polyethylene glycol 600 dioleate surfactant composition to another stirring container in sequence and stirring until clear; (3) Add the astragalus polysaccharide, transfer factor and thymopentin immunostimulatory agent composition to a third container filled with purified water, and then simultaneously add the base oil composition and the surfactant composition to a fourth container under stirring at room temperature. After the addition is completed, continue stirring at room temperature, then add the immunostimulatory agent composition, continue stirring, and finally obtain adjuvant 2 by homogenization.
6. The method for using the low-temperature emulsified water-in-oil-in-water adjuvant according to claim 4, characterized in that: The method of use comprises the following steps: (1) First, the antigen is diluted with phosphate buffer, which is used as the aqueous phase; (2) Weigh adjuvant 1; (3) The aqueous phase and adjuvant are precooled in a water bath at 6°C ± 2°C. When the internal temperature of the aqueous phase and the water-in-oil-in-water adjuvant reaches 8°C ± 2°C, emulsification begins to be performed to obtain a vaccine emulsion.
7. The method for using the low-temperature emulsified water-in-oil-in-water adjuvant according to claim 5, characterized in that: The method of use comprises the following steps: (1) First, the antigen is diluted with phosphate buffer, which is used as the aqueous phase; (2) Weigh adjuvant 2; (3) The aqueous phase and adjuvant 2 are precooled in a water bath at 6°C ± 2°C. When the internal temperature of the aqueous phase and the water-in-oil-in-water adjuvant reaches 8°C ± 2°C, emulsification begins to be performed to obtain a vaccine emulsion.
8. The method of use according to claim 6 or 7, characterized in that: The emulsification process in step (3) is as follows: adjuvant 1 or adjuvant 2 is stirred at a speed of 300-400 rpm, and the aqueous phase is slowly added. After the aqueous phase is added, stirring is continued for 20-30 minutes, and the temperature is maintained at 8°C ± 2°C.
9. Use of the low-temperature emulsified water-in-oil-in-water adjuvant according to any one of claims 1 to 3 in the preparation of animal vaccines.
Citation Information
Cited By
Self-emulsifying vaccine adjuvant containing submicron oil-in-water two-phase emulsion oil phase and preparation method of self-emulsifying vaccine adjuvant
CN121154804A
